Yongting Lai
Yongting Lai
1Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China
1,†,
Bing Feng
Bing Feng
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
2,†,
Mubalake Abudoureyimu
Mubalake Abudoureyimu
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
2,
Yingru Zhi
Yingru Zhi
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
2,
Hao Zhou
Hao Zhou
3Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China
3,
Ting Wang
Ting Wang
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
2,
Xiaoyuan Chu
Xiaoyuan Chu
1Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
1,2,
Ping Chen
Ping Chen
4Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China
4,*,
Rui Wang
Rui Wang
1Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
1,2,*
1Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China
2Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China
3Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China
4Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China
✉*Correspondence: Rui Wang wangrui218@163.com
*Ping Chen doc_pchen@126.com
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
†These authors have contributed equally to this work
Received 2020 Feb 8; Accepted 2020 Feb 17; Collection date 2020.
Keywords: hepatocellular carcinoma (HCC), sorafenib resistance, non-coding RNAs (ncRNAs), microRNAs (miRNAs), long non-coding RNAs (lncRNAs)
Copyright © 2020 Lai, Feng, Abudoureyimu, Zhi, Zhou, Wang, Chu, Chen and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
